Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) Research & Development (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Research & Development for 9 consecutive years, with $4.4 million as the latest value for Q4 2024.

  • On a quarterly basis, Research & Development fell 12.95% to $4.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $19.1 million, a 20.46% decrease, with the full-year FY2024 number at $19.1 million, down 20.46% from a year prior.
  • Research & Development was $4.4 million for Q4 2024 at SELLAS Life Sciences, up from $4.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $7.2 million in Q1 2023 to a low of $1.9 million in Q1 2020.
  • A 5-year average of $4.4 million and a median of $4.5 million in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 129.83% in 2021, then dropped 28.76% in 2024.
  • SELLAS Life Sciences' Research & Development stood at $2.8 million in 2020, then grew by 22.45% to $3.4 million in 2021, then soared by 72.3% to $5.8 million in 2022, then dropped by 12.81% to $5.1 million in 2023, then fell by 12.95% to $4.4 million in 2024.
  • Per Business Quant, the three most recent readings for SLS's Research & Development are $4.4 million (Q4 2024), $4.4 million (Q3 2024), and $5.2 million (Q2 2024).